drugset / Trial / NCT07625332
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Phase 2/3
Recruiting
60 enrolled
Northwell Health
Bronx Veterans Medical Research Foundation, Inc · collabKessler Institute for Rehabilitation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
Timeline
- Start
- 2026-06-15
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 8 mg | Oral |
| Subject | Galantamine | Small molecule | 16 mg | Oral |